Session » Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 332

A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis

9:00AM-11:00AM: Abstract Number: 354

A Longitudinal Cohort Study of Denosmab and Bisphosphonate for Prevention of Vertebral Fracture in Glucocorticoid-Induced Osteoporosis in Japanese

9:00AM-11:00AM: Abstract Number: 324

A Placebo Controlled Trial of Vertebral Fill Technique Vertebroplasty for Acute Painful Osteoporotic Fracture (VAPOUR Trial)

9:00AM-11:00AM: Abstract Number: 328

A Study of Serum Electrolyte Levels after Denosumab Administration

9:00AM-11:00AM: Abstract Number: 338

Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline

9:00AM-11:00AM: Abstract Number: 333

An Assessment of Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center

9:00AM-11:00AM: Abstract Number: 363

An Examination of Patient Knowledge and Education in Patients with Osteoporosis, Osteopenia and Normal Bone Mineral Density

9:00AM-11:00AM: Abstract Number: 339

Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study

9:00AM-11:00AM: Abstract Number: 331

Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

9:00AM-11:00AM: Abstract Number: 348

Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center

9:00AM-11:00AM: Abstract Number: 352

Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Chronic Kidney Disease Patients?

9:00AM-11:00AM: Abstract Number: 350

Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 353

Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis

9:00AM-11:00AM: Abstract Number: 347

Clinical Analysis of Tumor-Induced Osteomalacia Misdiagnosed As Spondyloarthritis: A Report of 18 Cases

9:00AM-11:00AM: Abstract Number: 343

Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients

9:00AM-11:00AM: Abstract Number: 326

Cortical Bone Changes in Pre- and Postmenopausal Healthy Women Measured with HR-pQCT

9:00AM-11:00AM: Abstract Number: 337

Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability

9:00AM-11:00AM: Abstract Number: 327

Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 325

Ebselen Is a Potential Anti-Osteoporosis Agent By Suppressing RANK Ligand-Induced Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo

9:00AM-11:00AM: Abstract Number: 323

Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study

9:00AM-11:00AM: Abstract Number: 349

Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis

9:00AM-11:00AM: Abstract Number: 341

Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 362

Evaluation of Osteoporosis Risk Factors in Lung Transplant Patients

9:00AM-11:00AM: Abstract Number: 329

Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 355

Fracture Incidence Rates in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 335

High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 340

Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!

9:00AM-11:00AM: Abstract Number: 358

Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California

9:00AM-11:00AM: Abstract Number: 346

Interest of Bone Texture Assessment By Trabecular Bone Score (TBS) in Kidney Transplants Recipients

9:00AM-11:00AM: Abstract Number: 344

Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies

9:00AM-11:00AM: Abstract Number: 365

Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.

9:00AM-11:00AM: Abstract Number: 357

Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment

9:00AM-11:00AM: Abstract Number: 360

Osteoporosis Prevalence in Lung Transplant Patients

9:00AM-11:00AM: Abstract Number: 356

Osteoporotic Fracture As the Main Risk Factor in the Detection of Osteoporosis in Men Under 70 Years

9:00AM-11:00AM: Abstract Number: 366

Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy

9:00AM-11:00AM: Abstract Number: 351

Pre-Operative Magnetic Resonance Imaging Can Help in Predicting Two-Year Readmission in Acute Severe Osteoporotic Vertebral Fracture after Vertebroplasty

9:00AM-11:00AM: Abstract Number: 334

Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study

9:00AM-11:00AM: Abstract Number: 342

Presence of Vertebral Fractures and Disc Disease in Post Menopausal Females with Height Loss As a Possible Screening Method for Osteoporosis

9:00AM-11:00AM: Abstract Number: 321

Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis

9:00AM-11:00AM: Abstract Number: 330

Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 364

Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density

9:00AM-11:00AM: Abstract Number: 322

The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort

9:00AM-11:00AM: Abstract Number: 359

The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk

9:00AM-11:00AM: Abstract Number: 361

The Effect of Immunosuppressive and Antiresorptive Therapy on Bone Mineral Density in Lung Transplant Patients

9:00AM-11:00AM: Abstract Number: 345

The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 336

The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].